

1 **Qualitative assessment of SARS-CoV-2-specific antibody avidity by lateral flow**
2 **immunochromatographic IgG/IgM antibody assay**

3 Arantxa Valdivia¹, Ignacio Torres¹, Dixie Huntley¹, María Jesús Alcaraz¹, Eliseo
4 Albert¹, Javier Colomina¹, Josep Ferrer¹, Arturo Carratalá², David Navarro^{1,3}

5 ¹*Microbiology Service, Hospital Clínico Universitario, INCLIVA Research Institute,*
6 *Valencia, Spain.*

7 ²*Medical Biochemistry and Clinical Analysis Service, Hospital Clínico Universitario,*
8 *INCLIVA Research Institute, Valencia, Spain.*

9 ³*Department of Microbiology, School of Medicine, University of Valencia, Valencia,*
10 *Spain.*

11

12 **Correspondence:** David Navarro, Microbiology Service, Hospital Clínico
13 Universitario, Instituto de Investigación INCLIVA, Valencia, and Department of
14 Microbiology, University of Valencia, Valencia, Spain. Av. Blasco Ibáñez 17, 46010
15 Valencia, Spain. Phone: 34(96)1973500; Fax: 34(96)3864173; Email:
16 david.navarro@uv.es.

17

18

19

20

21

22

23

24 **Abstract**

25 Qualitative assessment of SARS-CoV-2-specific antibody avidity was conducted using
26 an urea (6M) dissociation test performed on a lateral flow immunochromatographic
27 IgG/IgM device. We included a total of 76 serum specimens collected from 57 COVID-
28 19 patients, of which 39 tested positive for both IgG and IgM and 37 only for IgG. Sera
29 losing IgG reactivity after urea treatment (n=28) were drawn significantly earlier
30 ($P=0.04$) after onset of symptoms than those which preserved it (n=48). This assay may
31 be helpful to estimate the time of acquisition of infection in patients with mild to severe
32 COVID-19.

33

34 **Key words:** SARS-CoV-2, Covid-19, antibodies, avidity, urea dissociation.

35

36

37

38

39

40

41

42

43

44

45 Detection of SARS-CoV-2 RNA in respiratory tract specimens by reverse-transcription-
46 based PCR (RT-PCR) assays is the mainstay of COVID-19 diagnosis [1]. However, a
47 non-negligible fraction of COVID-19 patients test negative by RT-PCR on initial or
48 consecutive upper respiratory tract specimens, due to a number of non-mutually
49 exclusive pre-analytical or analytical factors [2]. Although serology testing is mainly
50 aimed at identifying individuals who have previously been exposed to SARS-CoV-2, it
51 may also aid in diagnosis of ongoing COVID-19, particularly in RT-PCR negative
52 patients who present at relatively late times after infection [3]. Knowledge of the precise
53 timing of infection may be of clinical and epidemiological relevance as viral shedding
54 in the upper respiratory tract (URT) seems to continue up to 7-9 days after onset of
55 symptoms in patients presenting with mild or moderate COVID-19 [4-6]. Often enough,
56 however, this cannot be accurately determined. Theoretically, virus-specific serum IgM
57 antibodies appear as soon as 7 days after infection and precede IgG seroconversion [7].
58 Nevertheless, both synchronous seroconversion of IgG and IgM, and IgM
59 seroconversion occurring later than IgG have been documented in the setting of
60 COVID-19 [8], casting doubt on the reliability of SARS-CoV-2 IgM as a biomarker of
61 acute infection. Affinity maturation is a process by which Th₂-cell-activated B cells
62 produce IgG antibodies with increased affinity for the antigen during the course of an
63 immune response [9], and avidity is defined as the combined affinities of a mixture of
64 polyclonal IgG molecules [10]. Presence of low-avidity IgGs has conventionally been
65 considered an indicator of recent infection [10]. Here, we carried out qualitative
66 assessment of SARS-CoV-2-specific antibody avidity using an urea dissociation test
67 performed on a lateral flow immunochromatographic device-LFIC- [11], and also
68 discuss the potential clinical use of this approach.

69 A total of 76 serum specimens collected from 57 COVID-19 patients were included in
70 this study. Microbiological diagnosis of COVID-19 was made by RT-PCR in 44
71 patients, using commercially-available RT-PCRs on upper respiratory tract specimens
72 (URT) [12,13], and by lateral flow immunochromatographic (LFIC) assay in the
73 remaining 13 patients (described below). Median age of patients (32 male and 25
74 female) was 66 years (range, 27-99 years). Forty-seven patients were admitted to our
75 center with pneumonia, while the remaining 10 patients presented with mild symptoms
76 not requiring hospitalization. Comorbid conditions including diabetes, cardiovascular
77 diseases, chronic obstructive pulmonary disease or malignancies were identified in 47
78 patients. Clinical charts were reviewed to establish the time of onset of symptoms. The
79 current study was approved by the Ethics Committee of Hospital Clínico Universitario
80 INCLIVA.

81 Qualitative assessment of SARS-CoV-2 antibody avidity was carried out using the
82 ALLTEST 2019-nCoV IgG/IgM Rapid Test Cassette (Hangzhou ALLTEST Biotech
83 Co., Ltd. Hangzhou, China), which uses a recombinant SARS-CoV-2 N protein as the
84 antigen, following the manufacturer's recommendations [14]. Cryopreserved specimens
85 (-80°C) were thawed and used for the experiments. A volume of 10µL of serum was
86 diluted into 1 mL of sample buffer before depositing (100 µL) into the appropriate
87 location of the cassette (Test T-hole). When the fluid was about to reach the absorbent
88 pad, 100 µL of sample buffer containing 6M urea was added to the T hole on the card.
89 Serum specimens were run in parallel in the absence of urea treatment. Each reading
90 was carried out independently by two observers after 20 min incubation. Appearance of
91 either strong or weak sharp bands at the T line was recorded as a positive result.
92 Absence of discernible lines was recorded as negative. Complete disappearance of

93 reactive lines after urea treatment was interpreted as presence of low-avidity antibodies,
94 whereas their persistence was taken to indicate high-avidity antibody presence.

95 The Mann-Whitney U-test was used for comparison of medians. P values <0.05 were
96 deemed to be statistically significant. The statistical package SPSS, version 21.0 (SPSS
97 Inc., USA) was employed.

98 Out of the 76 sera, 39 tested positive for both IgG and IgM and 37 only for IgG.
99 IgG+/IgM+ and IgG+/IgM- sera were obtained at a median of 20 days (range, 1-48
100 days) and 24 days (range, 6-59) after onset of symptoms, respectively ($P=0.13$). In line
101 with previous observations [8], our data highlighted the wide variability in the kinetics
102 of IgM and IgG detection across Covid-19 patients, which detracted from the reliability
103 of IgM presence as a marker of acute infection.

104 Following urea treatment, IgG reactivity disappeared in 28 sera and persisted in 48. Sera
105 losing IgG reactivity were obtained significantly earlier ($P=0.04$) after onset of
106 symptoms than those preserving it (median, 14.5 days; range, 1-45 days vs. median, 23
107 days; range, 5-59 days, respectively), although a certain degree of overlap was seen.
108 Based upon the assumption that viable SARS-CoV-2 can be detected in URT specimens
109 up to 9 days after symptoms onset [4-6], we grouped sera into two categories according
110 to whether they were drawn either prior to ($n=10$) or after day 9 ($n=66$) since symptoms
111 onset. Low-avidity IgGs were detected in 8 out of the 10 former sera, and in 21 of the
112 66 latter sera ($P=0.01$).

113 At least two consecutive sera were available from 15 patients (Table 1). Acquisition of
114 high-avidity IgG antibodies in our system was clearly time-dependent, usually occurring
115 3 weeks after onset of symptoms, although in a few patients it could be documented

116 earlier (patients 4, 5 and 15). This observation is in keeping with the idea that the
117 dynamics of antibody affinity maturation varies across individuals [7,10].

118 IgM reactivity was lost in 17 out of 39 sera after urea dissociation treatment, whereas it
119 remained in 22. The time elapsed since onset of symptoms did not differ across
120 comparison groups (median 24 days; range 1-45 days vs. 14.5 days; range 2-48 days,
121 respectively; $P=0.14$). Sera testing positive for rheumatoid factor (RF) IgM have been
122 shown to yield false-positive IgM reactivity in a SARS-CoV-2 LFIC assay, and it has
123 been reported that RF interference could be eliminated in most sera after urea
124 dissociation [11]. This observation was validated in the current study: 5 out of 14 sera
125 with leftover sample available that had lost IgM reactivity in the presence of urea tested
126 positive for RF (median 18 IU/ml; range, 17 to 46 IU/ml; normal values <14 IU/ml).
127 Collectively, these data suggest that SARS-CoV-2 N protein-reactive IgM avidity may
128 vary across Covid-19 patients, regardless of the infection acquisition time; elucidation
129 of whether this variability may impact on IgM functionality, and ultimately on Covid-19
130 prognosis could be an interesting focus of future research.

131 A total of 9 sera from patients with seasonal human coronavirus infection occurring
132 prior to the epidemic outbreak in our Health Department were also included in the
133 current study. Coronaviruses were detected in URT specimens by a multiplex PCR
134 assay (The NxTAG® Respiratory Pathogen Panel; Luminex Corp, Austin, TX, USA).
135 Seven patients had coronavirus 229E and 2 patients had dual infections caused by
136 coronavirus 229E and HKU1 and coronavirus 229E and NL63. Sera had been obtained
137 at a median of 3 weeks after diagnosis. Only one of the 9 sera tested IgG-positive, yet
138 reactivity was lost following urea treatment. This suggested, but did not prove, that IgG
139 antibodies targeting seasonal coronaviruses and cross-reacting with SARS-CoV-2 may
140 display low avidity.

141 In summary, we adapted a commercially-available LFIC IgG/IgM assay for qualitative
142 assessment of SARS-CoV-2 antibody avidity that may be helpful to estimate the time of
143 acquisition of infection in patients with mild to severe COVID-19. Our approach should
144 be validated using conventional quantitative ELISA or CLIA avidity assays and also in
145 cohorts including both asymptomatic and paucisymptomatic individuals. Further studies
146 are warranted to elucidate how the kinetics of IgG avidity maturation correlates with
147 that of virus excretion in the URT, to determine the extent to which contagiousness of
148 COVID-19 patients can be inferred from absence of high-avidity IgGs and determine
149 whether avidity of SARS-CoV-2-specific IgGs impact on clinical outcomes.

150 **Acknowledgements**

151 We are grateful to all personnel working at Microbiology Service of Hospital Clínico
152 Universitario for their unwavering commitment in the fight against Covid-19. We are
153 indebted to all colleagues who attended the patients, in particular to Josep Redón, María
154 Luisa Blasco, Jaime Signes-Costa, María José Galindo, and María José Forner.

155 **Funding information**

156 No public or private funds were used for the current study.

157 **Compliance with ethical standards**

158 **Conflict of interest**

159 The authors declare no conflicts of interest.

160 **Ethical approval**

161 The current study was approved by the Ethics Committee of Hospital Clínico
162 Universitario INCLIVA (2020-04).

163 **Informed consent**

164 Written informed consent was waived by the Ethics committee.

165 **References**

166 1. Laboratory testing strategy recommendations for COVID-19: interim guidance.

167 WHO/2019-nCoV/lab_testing/2020.1

168 2. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P,

169 del Campo R, Ciapponi A, et al. False-negative results of initial RT-PCR assays for

170 Covid-19: a systematic review. *MedRxiv preprint* 2020; doi:

171 <https://doi.org/10.1101/2020.04.16.20066787>.

172 3. Özçürümez MK, Ambrosch A, Frey O, Haselmann V, Holdenrieder S, Kiehntopf M,

173 et al. SARS-CoV-2 Antibody Testing - Questions to be asked. *J Allergy Clin Immunol.*

174 2020 ; S0091-6749(20)30739-9. doi: 10.1016/j.jaci.2020.05.020.

175 4. T To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal

176 profiles of viral load in posterior oropharyngeal saliva samples and serum antibody

177 responses during infection by SARS-CoV-2: an observational cohort study. *Lancet*

178 *Infect Dis* 2020;20:565-574.

179 5. V Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.

180 Virological assessment of hospitalized patients with COVID-2019. *Nature*

181 2020;581:465-469.

182 6. Bullard J, Dust K, Funk D, Strong JE, Alexander D, Garnett L, et al. Predicting

183 infectious SARS-CoV-2 from diagnostic samples. *Clin Infect Dis* 2020 ; ciaa638. doi:

184 10.1093/cid/ciaa638.

- 185 7. Schlomchik M, Janeway C, Travers P, Walport M, Schlomchik M. The distribution
186 and functions of immunoglobulin isotypes. In: *Immunobiology: The Immune System in*
187 *Health and Disease*, 5th ed. Garland Publishing, New York, NY, 2001.
- 188 8. Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to
189 SARS-CoV-2 in patients with COVID-19. *Nat Med* 2020 Apr 29. doi: 10.1038/s41591-
190 020-0897-1.
- 191 9. Teng G, Papavasiliou FN. Immunoglobulin somatic hypermutation. *Annu Rev Genet*
192 2007;41:107-120.
- 193 10. Hazell SL. Clinical utility of avidity assays. *Expert Opin. Med. Diagn* 2007 ; 1:511–
194 519.
- 195 11. Wang Q, Du Q, Guo B, Mu D, Lu X, Ma Q, et al. A Method To Prevent SARS-
196 CoV-2 IgM False Positives in Gold Immunochromatography and Enzyme-Linked
197 Immunosorbent Assays. *J Clin Microbiol* 2020 ; 58(6):e00375-20.
- 198 12. Blasco ML, Buesa J, Colomina J, Forner MJ, Galindo MJ, Navarro J, et al. Co-
199 detection of respiratory pathogens in patients hospitalized with Coronavirus viral
200 disease-2019 pneumonia. *J Med Virol* 2020 Apr 22. doi: 10.1002/jmv.25922.
- 201 13. Torres I, Albert E, Navarro D. Pooling of nasopharyngeal swab specimens for
202 SARS-CoV-2 detection by RT-PCR. *J Med Virol* 2020 May 5:10.1002/jmv.25971. doi:
203 10.1002/jmv.25971.
- 204 14. Package Insert. ALLTEST 2019-nCoV IgG/IgM Rapid Test Cassette, Hangzhou
205 ALLTEST Biotech Co., Ltd. Hangzhou, China. <https://www.siloambio->
206 [tech.com/en/product_1297294.html](https://www.siloambio-tech.com/en/product_1297294.html).

207